Clinical Trial

Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

Name: Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia — clinical trial record (NCT07686263)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The purpose of the study is to evaluate the relapse prevention of KarXT in the treatment of participants with Schizophrenia

Trial Details

NCT Number	NCT07686263
Lead Sponsor	Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Conditions	Schizophrenia
Enrollment	472 participants
Start Date	2026-09-03
Primary Completion	2029-03-03 (estimated)
Study Completion	2029-03-03 (estimated)
Updated on ClinicalTrials.gov	2026-07-07